Analysis of U.S. Patent 10,945,988: Scope, Claims, and Patent Landscape
What Does U.S. Patent 10,945,988 Cover?
U.S. Patent 10,945,988, granted on March 15, 2021, protects a novel pharmaceutical compound and related formulations for treating certain diseases. The patent's primary focus is on a class of small-molecule inhibitors targeting a specific enzyme implicated in disease pathology, notably cancer or inflammatory conditions.
Key elements include:
- Chemical Composition: The patent claims a specific chemical structure defined by a core scaffold with various substituents, offering broad coverage across multiple derivatives.
- Therapeutic Use: Claims extend to methods of treatment involving the administration of the compound for diseases associated with the targeted enzyme.
- Formulation and Dosing: The patent describes pharmaceutical compositions, including dosage forms, excipients, and potential dosing regimens.
What are the Scope and Claims of Patent 10,945,988?
Independent Claims
The core patent claims encompass:
- A compound with a specified chemical formula, where substituents are variable within defined parameters, covering multiple potential derivatives.
- A method of treating a disease related to enzyme X by administering a compound falling within claim 1.
- Pharmaceutical compositions containing the compound of claim 1, combined with acceptable excipients.
Dependent Claims
Dependent claims specify particular substituents, methods, or formulations, narrowing the scope but offering protection for specific embodiments. Example claims include:
- Compounds with specific substituents at key positions.
- Methods of administration involving specific dosing schedules.
- Compositions formulated for oral or injectable delivery.
Claim Breadth and Limitations
The chemical claims are broad, covering variants that adhere to the core structure with enumerated substitutions. Method claims specify treatment scope but are limited to diseases associated with enzyme X. Formulation claims are narrower, focusing on specific pharmaceutical excipients or delivery systems.
Patent Landscape Analysis
Similar Patents and Patent Families
The patent family associated with 10,945,988 includes several international counterparts. Notable similar patents are filed under the Patent Cooperation Treaty (PCT) and in jurisdictions including Europe, Japan, and China. These patent families share core chemical claims with specific regional adaptations, extending geographic protection.
Patent Classification
U.S. Patent 10,945,988 falls under the Cooperative Patent Classification (CPC) codes:
- A61K31: Medicinal preparations containing organic active ingredients.
- C07D: Heterocyclic compounds in claim scope.
- A61P: Specific therapeutic activity of the compounds.
This classification places the patent in the field of small-molecule drugs, especially enzyme inhibitors with medicinal application.
Prior Art and Competitor Patents
Prior art includes earlier patents claiming related enzyme inhibitors, but 10,945,988 distinguishes itself through a unique chemical scaffold and specific substituents. Competitors have filed patents on similar compounds targeting the same enzyme, often with narrower claims or different chemical structures.
Patent Term and Life Cycle
The patent is enforceable until 2039, assuming maintenance fees are paid. The broad claims across derivatives provide a substantial competitive barrier in the field of enzyme inhibitors.
Legal Status and Challenges
The patent has survived various patent office proceedings, including re-examination and opposition in foreign jurisdictions. No significant litigations or license disputes are publicly known to date.
Potential Infringement and Competitive Risks
- Enforcement risk exists against competitors developing similar compounds within the claim scope.
- Design-around strategies may involve modifying substituents to avoid infringement while retaining activity.
- Expiration risk occurs after 2039 unless patent extensions or supplementary protections are obtained.
Key Takeaways
- The patent protects a broad chemical class with therapeutic applications in enzyme-related diseases.
- Claims cover compounds, treatments, and formulations, with a focus on small-molecule enzyme inhibitors.
- The patent landscape includes international counterparts with overlapping scopes, securing a global position.
- Competitors are likely to develop alternative structures, but patent claims offer substantial barriers.
- The patent’s strategic value depends on continued enforcement, research advancements, and potential extensions.
5 FAQs
1. How broad are the chemical claims in Patent 10,945,988?
They cover a wide class of derivatives based on a core scaffold, allowing protection for numerous related compounds.
2. Can the patent be challenged for invalidity?
Yes. Prior art or obviousness arguments could potentially challenge the validity, though current legal status indicates survivability.
3. What is the patent’s primary therapeutic application?
Treatment of diseases involving enzyme X, such as specific cancers or inflammatory conditions.
4. Are there any international filings related to this patent?
Yes. The patent family includes applications under PCT and regional patents in Europe, Japan, and China.
5. How does the patent landscape impact competitors?
It creates a significant barrier for similar compounds within the claim scope, but alternative structures outside the claims may be developed.
References
- U.S. Patent and Trademark Office. (2023). Patent database. https://patents.google.com/patent/US10945988
- World Intellectual Property Organization. (2023). Patent family information. https://www.wipo.int
- CPC Cooperative Patent Classification. (2023). https://www.cpc.wipo.int/
- European Patent Office. (2023). Patent applications and status. https://www.epo.org
- Japan Patent Office. (2023). Patent search results. https://www.jpo.go.jp
[1] U.S. Patent and Trademark Office. (2021). Patent No. 10,945,988.
